- 04/26/2018
- the eisai china scholarships program supports china’s education for 18 consecutive years
- 04/20/2018
- eisai to present latest data on perampanel and rufinamide at annual american academy of neurology meeting
- 04/19/2018
- world’s first bile acid transporter inhibitor “goofice® 5mg tablet” launched in japan
- 04/02/2018
- eisai submits supplemental new drug application to u.s. fda for fycompa® as treatment for pediatric patients with epilepsy
- 03/23/2018
- anticancer agent lenvima® approved for additional indication of unresectable hepatocellular carcinoma (hcc) in japan, first approval worldwide for lenvima for hcc
- 03/12/2018
- innovation, joint efforts, defense -- shinsei electronics management visited eisai (china) headquarter
- 01/11/2018
- eisai completes construction of oral solid dose production facility at new suzhou plant in china
- 12/27/2017
- anticancer agent lenvatinib designated for priority review and approval by china food and drug administration for hepatocellular carcinoma
- 12/13/2017
- aricept® approved for additional indication of severe alzheimer’s disease in china
- 10/31/2017
- new drug application of anticancer agent lenvatinib for hepatocellular carcinoma accepted in china
